NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
Travera Inc
Beijing Kejing Biotechnology Co., Ltd.
Geneplus-Beijing Co. Ltd.
Sorrento Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Galectin Therapeutics Inc.